已收录 272976 条政策
 政策提纲
  • 暂无提纲
Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.
[摘要] Background Pyoderma gangraenosum is an immune-mediated, inflammatory, neutrophilic dermatosis of unknown etiology, which represents one of the extraintestinal manifestations of inflammatory bowel disease. It is a rare disease that occurs in less than 1% of patients with inflammatory bowel disease and with the same ratio in patients with Crohn's disease and ulcerative colitis.Main observations A 36-year-old woman was diagnosed with ulcerative colitis 6 years before admission to our dermatology department with an acute disseminated pyoderma gangraenosum with mucosal involvement, during a flare of ulcerative colitis. Disease progression was interrupted by intravenous administration of the tumor necrosis factor-α inhibitor infliximab at 5 mg/kg at weeks 0, 2, and 6 (1st cycle) and every 8 weeks thereafter. Improvement of intestinal, skin and oral manifestations was evident already after the 1st cycle of treatment and has been maintained since (at least 16 months).Conclusions This case report is one of very few on disseminated pyoderma gangraenosum with oral involvement complicating ulcerative colitis, where infliximab was shown to have a rapid efficacy on skin, mucosal and bowel symptoms.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 皮肤病学
[关键词] inflammatory bowel disease;mesalazine mucous membranes;pyoderma gangrenosum;TNF-alpha [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文